Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discuss findings on BGJ398 in patients with previously treated advanced/metastatic urothelial carcinoma with FGFR3 alterations (Abstract 4517).
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant...
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discuss findings from this phase III ...
Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completi...
Jonathan A. Ledermann, MD, of Cancer Research UK and University College London Cancer Trials Centre, and Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute,...
James R. Perry, MD, of Sunnybrook Health Sciences Centre, discusses findings of a phase III trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in...